Deal Watch: Editas, BlueRock Ink Cross-Licensing Technology Collaboration
Executive Summary
Combining Editas’ CRISPR gene-editing technology with BlueRock’s pluripotent stem cell capabilities, the companies hope to leverage each other to create novel gene therapies for cancer, neurological, cardiovascular and autoimmune diseases.
You may also be interested in...
First Results From Editas CRISPR Eye Therapy Underwhelm Investors
While rivals Intellia impressed with their first in vivo CRISPR gene-editing data, Editas’s first results in just two patients are not enough to convince investors.
Cipla CEO On Lung Leadership Beyond Asthma, AMR Plans
CEO Umang Vohra outlines where Cipla is heading in its priority areas of lung route therapies and antimicrobial resistance. He also weighs in on the simmering issue of intellectual property waivers for COVID-19 vaccines.
How Cipla Is Shaping Lung Leadership Beyond Asthma, AMR Plans
CEO Umang Vohra outlines where Cipla is heading in its priority areas of lung route therapies and antimicrobial resistance. He also weighs in on the simmering issue of intellectual property waivers for COVID-19 vaccines.